SEK 323.00
+3.40 (+1.06%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BIOA-B.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyNCT06671938Number of participants with adverse events (AEs) and serious adverse events (SAEs).Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: exidavnemab, Placebo Comparator | Parkinson Disease, Multiple System Atrophy | 38 | 2026-08-17 | 2026-03-10 |
| Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury SubjectsNCT02490501Proportion of subjects with an Adverse EventRandomized · Open-label · Treatment | Phase 1/2 | Completed | Procedure: SC0806 and rehabilitation · Other: Rehabilitation only | Spinal Cord Injury | 10 | Oct 2020actual | 2025-09-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19